| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 50 | KR 2 | 99.65 |
| Gastric Cancer Management and Outcomes | Lifetime | 189 | KR 12 | 99.46 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 179 | KR 3 | 99.40 |
| Peptidase Inhibition and Analysis | Lifetime | 176 | KR 2 | 99.19 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 126 | KR 13 | 99.13 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 382 | KR 8 | 99.11 |
| HER2/EGFR in Cancer Research | Lifetime | 176 | KR 5 | 99.18 |
| Gallbladder and Bile Duct Disorders | Lifetime | 206 | KR 12 | 98.95 |
| Colorectal Cancer Treatments and Studies | Lifetime | 281 | KR 10 | 99.08 |
| Neuroendocrine Tumor Research Advances | Lifetime | 495 | KR 6 | 98.29 |
| Lung Cancer Treatments and Mutations | Lifetime | 984 | KR 39 | 98.11 |
| Metastasis and carcinoma case studies | Lifetime | 376 | KR 61 | 97.21 |
| Cancer Diagnosis and Treatment | Lifetime | 780 | KR 8 | 96.46 |
| PARP inhibition in cancer therapy | Lifetime | 331 | KR 4 | 96.04 |
| Fibroblast Growth Factor Research | Lifetime | 760 | KR 7 | 91.56 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 3 | KR 1 | 99.91 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 25 | KR 1 | 99.54 |
| Peptidase Inhibition and Analysis | 2021-2025 | 11 | KR 2 | 99.58 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 12 | KR 1 | 99.41 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 29 | KR 4 | 99.65 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 17 | KR 3 | 99.33 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 52 | KR 1 | 98.65 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 333 | KR 12 | 98.71 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 111 | KR 6 | 98.45 |
| HER2/EGFR in Cancer Research | 2021-2025 | 82 | KR 7 | 98.66 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 126 | KR 3 | 96.97 |
| Fibroblast Growth Factor Research | 2021-2025 | 35 | KR 3 | 93.54 |
| Pediatric Hepatobiliary Diseases and Treatments | 2021-2025 | 154 | KR 5 | 94.07 |
| PARP inhibition in cancer therapy | 2021-2025 | 215 | KR 7 | 93.01 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 436 | KR 9 | 91.94 |
| Colorectal and Anal Carcinomas | 2021-2025 | 935 | KR 37 | 82.38 |
| Cancer Diagnosis and Treatment | 2021-2025 | 859 | KR 13 | 74.97 |
| Metastasis and carcinoma case studies | 2021-2025 | 967 | KR 117 | 75.40 |
| Oral and gingival health research | 2021-2025 | 471 | KR 3 | 66.54 |
